Welcome to our dedicated page for Ambac Finl Group SEC filings (Ticker: AMBC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AMBC SEC filings page on Stock Titan aggregates regulatory documents for Ambac Financial Group, Inc., which has been renamed Octave Specialty Group, Inc. According to an 8-K filing, the company amended its certificate of incorporation to adopt the Octave Specialty Group, Inc. name, with Ambac Financial Group, Inc. identified as the former name. These filings provide a detailed record of the company’s evolution from a financial guarantee-focused holding company to a specialty property and casualty insurance and insurance distribution platform.
Users can review Form 8-K current reports that describe material events such as the sale of Ambac Assurance Corporation and Ambac Assurance UK Limited to entities managed by Oaktree Capital Management, the acquisition of ArmadaCorp Capital, LLC and ArmadaCare, and the entry into senior secured credit facilities used in part to finance acquisitions. Other 8-K filings cover the name change to Octave Specialty Group, Inc., changes in the company’s independent registered public accounting firm, and executive compensation and employment agreements.
In addition to event-driven reports, investors typically consult annual reports on Form 10-K and quarterly reports on Form 10-Q for comprehensive financial statements, segment disclosures for Insurance Distribution and Specialty P&C Insurance, and discussions of risk factors and business strategy. While specific 10-K and 10-Q documents are not summarized here, they are accessible through EDGAR and provide context on revenues from commissions, program fees, and net premiums earned, as well as underwriting results at Everspan Group and related entities.
The filings page also surfaces information on insider and governance-related disclosures that may appear in proxy statements and ownership reports, alongside exhibits such as credit agreements, purchase agreements, and investor rights agreements. Stock Titan enhances access to these materials with AI-powered summaries that highlight key terms, structural changes, and financial implications, helping users interpret lengthy documents more efficiently.
By using this page, researchers can trace the regulatory history associated with the AMBC ticker, understand the transactions that enabled the shift to a pure-play MGA and specialty insurance platform, and follow the formal documentation of the company’s rebranding to Octave Specialty Group, Inc. and related governance changes.
Octave Specialty Group, Inc. filed an 8-K describing its completed acquisition of ArmadaCorp Capital, LLC for total consideration of approximately $250.0 million in cash, funded in part by $120.0 million of borrowings made at closing. The company explains that this transaction, referred to as the ArmadaCorp Transaction, closed on October 31, 2025.
The filing primarily provides historical and pro forma financial information related to the acquired business. It includes unaudited consolidated financial statements of ArmadaCorp as of and for the nine months ended September 30, 2025 and 2024, and audited financial statements for the years ended December 31, 2024 and 2023. It also provides unaudited pro forma combined financial information for Octave Specialty Group, including a combined balance sheet as of September 30, 2025 and combined statements of operations for the year ended December 31, 2024 and the nine months ended September 30, 2025, so readers can see how the acquisition might have affected the company’s results.
Octave Specialty Group Inc. reported a new equity award to one of its directors. On January 1, 2026, the director received 4,524 restricted stock units (RSUs), each representing a right to receive one share of Octave Specialty Group common stock. The RSUs were recorded at an exercise price of $0 and are held as direct beneficial ownership, bringing the director’s total derivative securities beneficially owned to 8,650.
The RSUs granted on January 1, 2026 are scheduled to fully vest on January 1, 2027. Once vested, they convert into shares of common stock on the vesting date or when the director leaves the Board, unless the director has elected to defer settlement.
Octave Specialty Group Inc. director reports new equity award. A board member of Octave Specialty Group Inc. recorded a grant of 4,524 restricted stock units (RSUs) effective January 1, 2026. Each RSU represents a contingent right to receive one share of the company’s common stock.
The RSUs are scheduled to vest on January 1, 2027. Once vested, they will convert into shares of common stock on the earlier of the vesting date or the date the director leaves the company’s Board of Directors, subject to any deferral election by the reporting person. Following this transaction, the filing shows 8,650 derivative securities beneficially owned on a direct basis.
Octave Specialty Group Inc. director reported receiving restricted stock units that could convert into common shares. On January 1, 2026, the reporting person was granted 4,524 restricted stock units (RSUs), each tied to one share of Octave Specialty Group Inc. common stock. The RSUs are listed with a price of $0 and are shown as a direct holding.
The filing states that these RSUs will vest on January 1, 2027. Once vested, they will settle into shares of common stock on the earlier of the vesting date or the date the director resigns from, or otherwise ceases to be a member of, the company’s Board of Directors, unless the director elects to defer settlement. After this transaction, the filing shows 8,650 derivative securities beneficially owned.
Octave Specialty Group Inc. reported an equity award to a board member. On January 1, 2026, the director received 4,524 restricted stock units (RSUs), each representing a contingent right to one share of Octave Specialty Group common stock. These RSUs are scheduled to vest on January 1, 2027, and any vested RSUs will convert into common shares on the earlier of the vesting date or when the director leaves the Board, unless the director elects to defer settlement. After this grant, the director beneficially owns 8,650 derivative securities in the form of RSUs.
Octave Specialty Group Inc. reported an equity award to a board member in the form of restricted stock units. On January 1, 2026, the director received 4,524 restricted stock units (RSUs), each representing a contingent right to receive one share of Octave Specialty Group common stock. These RSUs are scheduled to vest on January 1, 2027. Once vested, they will convert into common shares on the earlier of the vesting date or the date the director leaves the company’s Board of Directors, unless the director elects to defer settlement. After this grant, the reporting person held a total of 8,650 derivative securities related to the company’s stock in direct ownership.
Octave Specialty Group Inc. reported an equity grant to a board member. A director received 4,524 restricted stock units (RSUs) of Octave Specialty Group Inc. common stock on January 1, 2026. Each RSU represents a right to receive one share of common stock and was granted at a price of $0 per unit. The RSUs are scheduled to vest on January 1, 2027. Once vested, they will convert into common shares on the earlier of the vesting date or the date the director ceases to serve on the company’s Board of Directors, unless the director elects to defer settlement. Following this grant, the reporting person holds 8,650 derivative securities directly.
Octave Specialty Group Inc. director and Chief Executive Officer reported buying additional company stock. On 01/02/2026, a Form 4 shows an open-market purchase of 12,000 shares of common stock at a price of $7.59 per share, coded as an acquisition transaction. After this trade, the reporting person beneficially owns 1,033,777 shares of Octave Specialty Group Inc. common stock in direct ownership. The filing reflects a single, straightforward insider purchase with no derivative securities activity disclosed.
Octave Specialty Group Inc. disclosed that one of its officers, serving as Senior Managing Director and General Counsel, filed an initial insider ownership report effective 12/11/2025.
The report states that this reporting person currently has no securities beneficially owned, and it was signed by attorney-in-fact William J. White on 12/17/2025.
Octave Specialty Group, Inc., formerly Ambac Financial Group, is changing its independent auditor as part of an audit firm rotation. The Audit Committee conducted a competitive request-for-proposal process and decided not to continue with KPMG, which has audited the company since 1985.
KPMG will complete audits of the 2025 financial statements and internal control over financial reporting. Its opinions on the 2023 and 2024 financial statements and internal controls were unqualified, and the company reports no disagreements or reportable events with KPMG through December 10, 2025. The Audit Committee approved the appointment of Ernst & Young LLP as the new independent registered public accounting firm for the 2026 audit, subject to completion of EY’s client acceptance procedures and engagement agreements.
FAQ
What is the current stock price of Ambac Finl Group (AMBC)?
What is the market cap of Ambac Finl Group (AMBC)?
